Gene Therapy Trial Can Restart After Patient Death, FDA Says. The Sector Remains Depressed.

The biotech Rocket Pharmaceuticals said the Food and Drug Administration would allow it to continue a gene therapy trial the agency had put on hold in late May, when a patient in the trial died. In the following months, investor enthusiasm for gene therapies waned even further, as what was once the biggest idea in biotech delivered even more disappointments and safety worries. Rocket’s relatively quick reprieve is good news for the stock, and suggests that the FDA remains actively supportive of gene therapy development.

Continue Reading

View Comments